Avicenna Life Sci Master Fund LP - 02 Feb 2026 Form 3 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: LXRX
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 12 Feb 2026, 21:29:24 UTC
Source filing: View source filing
Reporting owner signature: AVICENNA LIFE SCI MASTER FUND LP, By: Avicenna Life Sci Master GP LLC, its GP By: /s/ Raymond Debbane, Name: Raymond Debbane Title: Chief Executive Officer

Key filing fact

Avicenna Life Sci Master Fund LP filed Form 3 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 12 Feb 2026.

Key facts

This page summarizes Avicenna Life Sci Master Fund LP's Form 3 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 21:29.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (2)

CIK 0002110935 Primary reporting owner

Avicenna Life Sci Master Fund LP

Relationship: Director, 10%+ Owner
Address: 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK
Signature: AVICENNA LIFE SCI MASTER FUND LP, By: Avicenna Life Sci Master GP LLC, its GP By: /s/ Raymond Debbane, Name: Raymond Debbane Title: Chief Executive Officer
Signature date: 12 Feb 2026

CIK 0002110936

Avicenna Life Sci Master GP LLC

Relationship: Director, 10%+ Owner
Address: 750 LEXINGTON AVENUE 30TH FLOOR, NEW YORK
Signature: AVICENNA LIFE SCI MASTER GP LLC, By: /s/ Raymond Debbane, Name: Raymond Debbane, Title: Chief Executive Officer
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,538,462
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares of common stock par value $0.001 per share (the "Common Stock") are directly held by Avicenna Life Sci Master Fund LP. The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.

Footnote F2

Each of the Reporting Persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC remarks

Invus Public Equities, L.P. directly holds 7,362,368 shares of Common Stock, Invus, L.P. directly owns 35,402,689 shares of Common Stock, Invus US Partners LLC directly owns 5,451,204 shares of Common Stock, Mr. Debbane directly owns 1,385,689 shares of Common Stock and Artal Participations S.a r.l. directly holds 154,734,327 shares of Common Stock, which securities are reported on a separate Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.